These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14290782)

  • 21. [The antibody level against influenza viruses in man during the course of immunization with TAB vaccines].
    GERTH HJ; WUNDT W
    Z Immun exp ther; 1962 Dec; 124():370-81. PubMed ID: 13947383
    [No Abstract]   [Full Text] [Related]  

  • 22. [ON THE EPIDEMIOLOGICAL AND VIROLOGICAL CHARACTERICS OF INFLUENZA PRESENT IN TASHKENT IN 1961].
    ILINA Ts; MEVZOS LM
    Med Zh Uzb; 1963 Dec; 12():49-53. PubMed ID: 14163194
    [No Abstract]   [Full Text] [Related]  

  • 23. Studies on complement fixation antigens of influenza virus. I. Type-specific and strainspecific complement fixation tests as compared with hemagglutination-inhibition test.
    CHANG SS; CHEN CY
    Taiwan Yi Xue Hui Za Zhi; 1961 Nov; 60():1010-25. PubMed ID: 13878105
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hemagglutination inhibition reaction as an indicator of humoral immunity in influenza: limitations of the method].
    Zaĭdes VM; Zhdanov VM
    Vopr Virusol; 1984; 29(1):4-8. PubMed ID: 6369785
    [No Abstract]   [Full Text] [Related]  

  • 25. [IDENTIFICATION OF INFLUENZA A2 STRAINS WITH THE COMPLEMENT FIXATION REACTION USING IMMUNE SERA WITH S-PARTICLES].
    GERTH HJ
    Z Hyg Infektionskr; 1964 Apr; 149():430-9. PubMed ID: 14214971
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of antibodies to neuraminidase of A2-Hong Kong and A2-Taiwan influenza viruses after administration of different Hong Kong vaccines and after natural infection in humans.
    Závadová H
    Acta Virol; 1973 Jul; 17(4):287-92. PubMed ID: 4148207
    [No Abstract]   [Full Text] [Related]  

  • 27. [PRODUCTION OF ANTINUCLEAR ANTIBODIES IN ANIMAL EXPERIMENTS. STUDIES ON THE IMMUNOLOGY OF VISCERAL LUPUS ERYTHEMATOSUS].
    HEIDE G; DEICHER H; HARTMANN F
    Dtsch Arch Klin Med; 1963 Dec; 209():144-65. PubMed ID: 14126762
    [No Abstract]   [Full Text] [Related]  

  • 28. A METHOD FOR INCREASING THE SENSITIVITY OF THE HEMAGGLUTINATION-INHIBITION TEST WITH EQUINE INFLUENZA VIRUS.
    BERLIN BS; MCQUEEN JL; MINUSE E; DAVENPORT FM
    Virology; 1963 Dec; 21():665-6. PubMed ID: 14100621
    [No Abstract]   [Full Text] [Related]  

  • 29. STUDIES OF PARAINFLUENZA VIRUSES. 3. ANTIBODY RESPONSES OF DIFFERENT ANIMAL SPECIES AFTER IMMUNIZATION.
    HSIUNG GD; CHANG PW; CUADRADO RR; ISACSON P
    J Immunol; 1965 Jan; 94():67-73. PubMed ID: 14256977
    [No Abstract]   [Full Text] [Related]  

  • 30. ENHANCED AVIDITY OF INFLUENZA ANTIBODIES AFTER REPEATED CONTACT OF MEN AND ANIMALS WITH A2 INFLUENZA VIRUS.
    ALEXANDROVA GI; YABROV AA; SMORODINTSEV AA
    Acta Virol; 1964 Sep; 8():385-95. PubMed ID: 14209622
    [No Abstract]   [Full Text] [Related]  

  • 31. [Influenza virus of the Hong Kong type isolated at Turin and in Piemont].
    Giuliani G; Paggi GC; Novara O
    G Batteriol Virol Immunol Ann Osp Maria Vittor Torino; 1970; 63(11):700-12. PubMed ID: 5002843
    [No Abstract]   [Full Text] [Related]  

  • 32. Infection with A2 Hong Kong influenza virus in domestic cats.
    Paniker CK; Nair CM
    Bull World Health Organ; 1970; 43(6):859-62. PubMed ID: 5314017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental infection of horses with A-equi 2-Miami-1-63 and human A2-Hong Kong 1-68 influenza viruses. II. Antibody response to the infection.
    Blaskovic D; Sabó A; Kapitáncik B; Styk B; Vrtiak O; Kaplan M
    Acta Virol; 1969 Nov; 13(6):507-14. PubMed ID: 4391718
    [No Abstract]   [Full Text] [Related]  

  • 34. The course of antibody development to influenza A2 strains; examined in the haemagglutination inhibition test with viruses of different sensitivity to homologous antibody.
    HARBOE A; REENAAS R
    Acta Pathol Microbiol Scand; 1959; 46():266-72. PubMed ID: 14399688
    [No Abstract]   [Full Text] [Related]  

  • 35. COFACTOR AND SPECIFIC ANTIBODIES AGAINST INFLUENZA VIRUSES. 8. ON THE DIFFERENT NATURE OF "ANTIBODY COFACTOR" AND COMPLEMENT.
    STYK B; KOCISKOVA D; HANA L
    Acta Virol; 1964 Nov; 8():496-506. PubMed ID: 14242988
    [No Abstract]   [Full Text] [Related]  

  • 36. [Complement fixation, hemagglutination inhibition and neuraminidase inhibition reactions in the seroepidemiologic evaluation of an influenza A epidemic].
    Volpi A; Ragona G; Gentile R; Cervelli G; De Felici A; Muzzi A
    Boll Ist Sieroter Milan; 1976 Sep; 55(4):287-91. PubMed ID: 1016581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of long-life radioisotopes Sr90 and Cs137 on the formation of antibodies to influenza A virus].
    Shubik VM
    Vopr Virusol; 1968; 13(5):592-5. PubMed ID: 5708929
    [No Abstract]   [Full Text] [Related]  

  • 38. Production of common colds in human volunteers by influenza C virus.
    Joosting AC; Head B; Bynoe ML; Tyrrell DA
    Br Med J; 1968 Oct; 4(5624):153-4. PubMed ID: 5681050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Persistence of anti-V hemagglutination-inhibiting antibodies and complement-fixing antibodies induced by administration of inactivated influenza vaccines].
    Profeta ML
    Ann Sclavo; 1972; 14(2):145-58. PubMed ID: 4669354
    [No Abstract]   [Full Text] [Related]  

  • 40. ANTIBODY IN MAN AGAINST A BOVINE STRAIN OF PARA-INFLUENZA VIRUS TYPE 3.
    SCHIOTT CR
    Acta Pathol Microbiol Scand; 1963; 59():239-44. PubMed ID: 14083769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.